ClinicalTrials.gg
TerminatedNCT03420781Updated Dec 22, 2021Results posted

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

A Phase 3 interventional study of Placebo and Relamorelin in Gastroparesis and Diabetes Mellitus, sponsored by Allergan. Terminated at 337 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-22.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The Relamorelin program is being terminated solely based on a business decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
467
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
3rd of 136
467 · median 36
Started
2018
with 11 others
Phase 3
12 of 184
none open now
Registered
90th of 184
by date
Lead sponsor
6 of 184
Allergan

Among the 184 studies in Gastroparesis with a site in United States, this one is the 3rd largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 12 in phase 3, and was the 90th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.

03

Conditions studied

  • Gastroparesis
  • Diabetes Mellitus

Keywords

  • diabetic gastroparesis
  • vomiting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all the following criteria apply:
  • Participant met all inclusion/exclusion criteria of either Protocol RLM-MD-01 (NCT03285308) or Protocol RLM-MD-02 (NCT03426345) and successfully completed the study
  • Able to provide written (IC) prior to any study procedures and willing and able to comply with study procedures
  • In the opinion of the investigator, the participant demonstrated adequate compliance with the study procedures in Study RLM-MD-01 or RLM-MD-02

Exclusion criteria

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:
  • Participant is not willing or able to abide by the restrictions regarding concomitant medicine use
  • Participant is planning to receive an drug (other than study treatment) or investigational device at any time during Study RLM-MD-03
  • Participant has an unresolved adverse event (AE) or a finding on physical examination, clinical laboratory test, or 12-lead (ECG) that, in the investigator's opinion, would limit the participant's ability to participate in or complete the study
  • Any other reason that, in the investigator's opinion, would confound proper interpretation of the study or expose a participant to unacceptable risk, including renal, hepatic or cardiopulmonary disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
467 participants (actual)

Study arms

  • Placebo comparator
    Treatment Period: Placebo

    Placebo-matching relamorelin injected subcutaneously twice daily for up to 40 weeks.

    Drug: Placebo

  • Experimental
    Treatment Period: Relamorelin 10 μg

    Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 40 weeks.

    Drug: Relamorelin

  • Experimental
    Randomized Withdrawal Period: Placebo then Relamorelin 10 μg

    Participants who received placebo-matching relamorelin injected subcutaneously twice daily for 40 weeks, followed by relamorelin 10 μg injected twice daily for up to 6 weeks in the Randomized Withdrawal (RW) Period.

    Drug: Placebo · Drug: Relamorelin

  • Experimental
    Randomized Withdrawal Period: Relamorelin 10 μg then Relamorelin 10 μg

    Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by relamorelin injected twice daily for up to 6 weeks in the RW Period.

    Drug: Relamorelin

  • Experimental
    Randomized Withdrawal Period: Relamorelin 10 μg then Placebo

    Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo-matching relamorelin injected twice daily for up to 6 weeks in the RW Period.

    Drug: Placebo · Drug: Relamorelin

Interventions

  • DrugPlacebo

    Placebo injected twice daily

  • Relamorelin 10 μg injected twice daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period

    Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to Week 12 of this study

  2. Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

    The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period.

    Time frame: Week 6 to Week 12

Secondary outcomes

  1. Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

    A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no nausea to 10=worst possible nausea. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)

  2. Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

    An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no abdominal pain to 10=the worst possible abdominal pain and was recorded in an e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)

  3. Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

    A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no bloating and 10=the worst possible bloating and was recorded in the e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)

  4. Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

    A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no feeling of fullness until finishing a meal (best) to 10=feeling full after only a few bites (worst). Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)

  5. Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period

    Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages (Week 37 to Week 40) of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 37 to Week 40)

  6. Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period

    The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during the last 4 weeks of the 40-week Treatment Period.

    Time frame: Week 37 to Week 40

  7. Change From Baseline to Week 40 in the Average Weekly Number of Vomiting Episodes of the Treatment Period

    The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. The average weekly number of vomiting episodes were derived as the average of the weekly number of vomiting episodes in the last 4 weeks of the 40-week Treatment Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 37 to Week 40)

  8. Change From Baseline to Week 46 in the Average Weekly DGSSS of the Randomized-Withdrawal Period

    Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). Average weekly scores are derived as the average of the weekly scores from the 6 weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 41 to Week 46)

  9. Change From Baseline to Week 46 in the Average Weekly Number of Vomiting Episodes of the Randomized-Withdrawal Period

    The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. Average weekly number of vomiting episodes are derived as the average of the weekly number of vomiting episodes from the six weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

    Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 41 to Week 46)

  10. Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.

    Time frame: First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 50 weeks)

  11. Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results

    Clinical Laboratory values included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to 46 weeks

  12. Number of Participants With Clinically Meaningful Trends for Vital Signs

    Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the results were clinically significant.

    Time frame: Up to 46 weeks

  13. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

    A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.

    Time frame: Up to 46 weeks

  14. Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)

    Time frame: Up to 46 weeks

  15. Number of Participants With Anti-relamorelin Antibody Testing Results

    A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay.

    Time frame: Up to 46 weeks

07

Results

Posted Dec 22, 2021

Participant flow

Treatment Period (40 Weeks)
Participant flow — Treatment Period (40 Weeks)
MilestoneTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Started236231000
Safety population235231000
Completed92105000
Not completed144126000
Withdrew: Adverse event16000
Withdrew: Lack of efficacy11000
Withdrew: Withdrawal by subject2216000
Withdrew: Lost to follow-up106000
Withdrew: Death22000
Withdrew: Physician decision34000
Withdrew: Protocol deviation02000
Withdrew: Study terminated by the sponsor10189000
Withdrew: Site terminated by the sponsor10000
Withdrew: Reason not specified30000
RW Period: 6 Weeks (Week 41 to Week 46)
Participant flow — RW Period: 6 Weeks (Week 41 to Week 46)
MilestoneTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Started00915943
Completed00855438
Not completed00655
Withdrew: Adverse event00020
Withdrew: Withdrawal by subject00002
Withdrew: Study terminated by the sponsor00633

Outcome measures

PrimaryChange From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period

Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to Week 12 of this study
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period
score on a scaleTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Baseline24.9 ± 5.6524.8 ± 6.28
Change from Baseline to Week 12-11.9 ± 9.43-11.2 ± 9.00
PrimaryPercentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period.

Time frame:
Week 6 to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
percentage of participantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period29.421.4
SecondaryPercentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no nausea to 10=worst possible nausea. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
percentage of participantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period46.043.2
SecondaryPercentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no abdominal pain to 10=the worst possible abdominal pain and was recorded in an e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
percentage of participantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period40.439.7
SecondaryPercentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no bloating and 10=the worst possible bloating and was recorded in the e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
percentage of participantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period38.338.4
SecondaryPercentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period

A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no feeling of fullness until finishing a meal (best) to 10=feeling full after only a few bites (worst). Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
percentage of participantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period36.636.2
SecondaryChange From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period

Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages (Week 37 to Week 40) of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 37 to Week 40)
Reported as:
Mean · score on a scale
Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period
score on a scaleTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Baseline24.9 ± 5.6524.8 ± 6.28
Change from Baseline to Week 40-13.3 ± 10.22-12.3 ± 9.20
SecondaryPercentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period

The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during the last 4 weeks of the 40-week Treatment Period.

Time frame:
Week 37 to Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period
percentage of participantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period19.118.8
SecondaryChange From Baseline to Week 40 in the Average Weekly Number of Vomiting Episodes of the Treatment Period

The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. The average weekly number of vomiting episodes were derived as the average of the weekly number of vomiting episodes in the last 4 weeks of the 40-week Treatment Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 37 to Week 40)
Reported as:
Mean · vomiting episodes per week
Change From Baseline to Week 40 in the Average Weekly Number of Vomiting Episodes of the Treatment Period
vomiting episodes per weekTreatment Period: PlaceboTreatment Period: Relamorelin 10 μg
Baseline6.8 ± 11.097.3 ± 11.52
Change from Baseline to Week 40-1.8 ± 17.51-5.4 ± 11.87
SecondaryChange From Baseline to Week 46 in the Average Weekly DGSSS of the Randomized-Withdrawal Period

Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). Average weekly scores are derived as the average of the weekly scores from the 6 weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 41 to Week 46)
Reported as:
Mean · score on a scale
Change From Baseline to Week 46 in the Average Weekly DGSSS of the Randomized-Withdrawal Period
score on a scaleRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Baseline25.7 ± 5.6525.7 ± 6.2524.4 ± 5.47
Change from Baseline to Week 46-13.4 ± 10.45-12.5 ± 9.71-12.5 ± 9.35
SecondaryChange From Baseline to Week 46 in the Average Weekly Number of Vomiting Episodes of the Randomized-Withdrawal Period

The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. Average weekly number of vomiting episodes are derived as the average of the weekly number of vomiting episodes from the six weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.

Time frame:
Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 41 to Week 46)
Reported as:
Mean · vomiting episodes per week
Change From Baseline to Week 46 in the Average Weekly Number of Vomiting Episodes of the Randomized-Withdrawal Period
vomiting episodes per weekRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Baseline6.1 ± 7.019.9 ± 11.924.2 ± 4.73
Change from Baseline to Week 46-1.8 ± 18.40-7.3 ± 10.23-1.8 ± 6.12
SecondaryNumber of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.

Time frame:
First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 50 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
ParticipantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)12913118128
SecondaryNumber of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results

Clinical Laboratory values included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to 46 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
ParticipantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Eosinophils Absolute Cell Count [10^9/liter(L)]: >3×Upper Limit of Normal Value (ULN)21011
Hematocrit (RATIO): >1.1×ULN12210
Hematocrit (RATIO): <0.9×Lower Limit of Normal Value (LLN)77402
Hemoglobin [grams (g)/L]: <0.9×LLN1314514
Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN14000
Mean Corpuscular Volume [femtoliter (fL)]: >1.1×ULN23100
Mean Corpuscular Volume (fL): <0.9×LLN40100
Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN02200
Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN64200
Platelet Count (Thrombocytes) (10^9/L): >1.5×ULN01000
Platelet Count (Thrombocytes) (10^9/L): <0.5×LLN10000
Red Blood Cell Count (10^12/L): >1.1×ULN10000
Red Blood Cell Count (10^12/L): <0.9×LLN48410
White Blood Cell Count (10^9/L): <0.7×LLN20000
Alanine Aminotransferase [Serum Glutamic Pyruvic Transaminase (SGPT)] [unit(U)/L]: >=3×ULN22021
Albumin (g/L): <0.9×LLN11101
Alkaline Phosphatase (U/L): >=3×ULN03000
Aspartate Aminotransferase [Serum Glutamic Oxaloacetic Transaminase (SGOT)] (U/L): >=3×ULN32000
Bicarbonate (HCO3) [millimoles (mmol)/L]: >1.1×ULN32110
Bicarbonate (HCO3) (mmol)/L: >0.9×LLN69241
Bilirubin, Total [micromoles(μmol)/L]: >1.5×ULN10000
Blood Urea Nitrogen (mmol/L): >1.2×ULN2920844
Calcium (mmol/L): >1.1×ULN10100
Calcium (mmol/L): <0.9×LLN10001
Chloride (mmol/L): <0.9×LLN21101
Cholesterol, Total, Fasting (mmol/L): >1.6×ULN41010
Creatinine (μmol/L): >1.3×ULN2216523
Glucose-Chemistry, Fasting (mmol/L): >2.5×ULN4133994
Glucose-Chemistry, Fasting (mmol/L): <0.9×LLN149422
Glycohemoglobin A1C: Increase of >=0.5%134138622628
Glycohemoglobin A1C: Increase of >=1%134138622628
Phosphorus (mmol/L): >1.1×ULN1012444
Phosphorus (mmol/L): <0.9×LLN43000
Potassium (mmol/L): <0.9×LLN00200
Protein, Total (g/L): >1.1×ULN01000
Protein, Total (g/L): <0.9×LLN01001
Triglycerides, Fasting (mmol/L): >=3×ULN911442
Uric Acid (Urate) (μmol/L): >1.1×ULN3131531
Uric Acid (Urate) (μmol/L): <0.9×LLN34100
SecondaryNumber of Participants With Clinically Meaningful Trends for Vital Signs

Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the results were clinically significant.

Time frame:
Up to 46 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Trends for Vital Signs
ParticipantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Number of Participants With Clinically Meaningful Trends for Vital Signs00000
SecondaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.

Time frame:
Up to 46 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
ParticipantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results32000
SecondaryNumber of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)
Time frame:
Up to 46 weeks
Reported as:
Count of participants · Participants
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)
ParticipantsTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)134138622628
SecondaryNumber of Participants With Anti-relamorelin Antibody Testing Results

A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay.

Time frame:
Up to 46 weeks

No measurements were reported for this outcome.

Adverse events

Collected over First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 50 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period: Placebo3/236 (1.3%)24/235 (10.2%)18/235 (7.7%)
Treatment Period: Relamorelin 10 μg2/231 (0.9%)20/231 (8.7%)27/231 (11.7%)
Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg0/91 (0%)3/91 (3.3%)0/91 (0%)
Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg0/59 (0%)2/59 (3.4%)0/59 (0%)
Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo0/43 (0%)1/43 (2.3%)0/43 (0%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Rib fractureInjury, poisoning and procedural complications0/2350/2310/910/591/43
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/2351/2310/910/591/43
SyncopeNervous system disorders1/2350/2310/911/591/43
Hypertensive encephalopathyNervous system disorders0/2350/2310/910/591/43
Acute kidney injuryRenal and urinary disorders4/2353/2310/910/591/43
Accelerated hypertensionVascular disorders0/2350/2310/910/591/43
Myocardial infarctionCardiac disorders0/2350/2310/911/590/43
Postinfarction anginaCardiac disorders0/2350/2310/911/590/43
Diabetic ketoacidosisMetabolism and nutrition disorders2/2353/2310/910/590/43
Coronary artery diseaseCardiac disorders3/2351/2310/910/590/43
Most frequent other events
Most frequent other events
EventTreatment Period: PlaceboTreatment Period: Relamorelin 10 μgRandomized Withdrawal Period: Placebo Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μgRandomized Withdrawal Period: Relamorelin 10 μg Then Placebo
Urinary tract infectionInfections and infestations13/23516/2310/910/590/43
HyperglycaemiaMetabolism and nutrition disorders7/23512/2310/910/590/43

Baseline characteristics

ITT Population included all participants who entered the 40-week treatment period.

Age, Continuous
Age, Continuous(years)Treatment Period: PlaceboTreatment Period: Relamorelin 10 μgTotal
Mean55.5 ± 11.1156.2 ± 11.5155.9 ± 11.30
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Period: PlaceboTreatment Period: Relamorelin 10 μgTotal
Female162166328
Male7465139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Period: PlaceboTreatment Period: Relamorelin 10 μgTotal
Hispanic or Latino8382165
Not Hispanic or Latino153149302
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Period: PlaceboTreatment Period: Relamorelin 10 μgTotal
American Indian or Alaska Native3811
Asian211839
Native Hawaiian or Other Pacific Islander000
Black or African American372158
White175183358
More than one race011
Unknown or Not Reported000
08

Study locations

337 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Digestive Health Specialist of the South East
    Dothan, Alabama 36305, United States
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • Alabama Medical Group, PC
    Mobile, Alabama 36608, United States
  • Del Sol Research Management, LLC
    Chandler, Arizona 85224, United States
  • Phoenix Clinical LLC.
    Phoenix, Arizona 85014, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85712, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Unity Health - Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • GW Research Inc
    Chula Vista, California 91910, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • Aurora Care Clinic, LLC
    Costa Mesa, California 92627, United States
  • Diagnamics Inc.
    Encinitas, California 92024, United States
  • VVCRD Research
    Garden Grove, California 92845, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • Torrance Clinical Research Institute, Inc.
    Lomita, California 90717, United States
  • Angel City Research Inc.
    Los Angeles, California 90026, United States
  • TriWest Research Associates
    Poway, California 92064, United States
  • Medical Associates Research Group, Inc
    San Diego, California 92123, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Upland Clinical Research
    Upland, California 91786, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Synexus Clinical Research US, Inc. - Colorado Springs Family Practice
    Colorado Springs, Colorado 80909, United States
  • Gastroenterology Associates of Fairfield County, P.C.
    Bridgeport, Connecticut 06606, United States
  • TrialSpark, Inc.
    Washington, District of Columbia 20017, United States
  • Innovative Research of West FL, Inc.
    Clearwater, Florida 33756, United States
  • West Central Gastroenterology
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • ALL Medical Research LLC
    Cooper City, Florida 33024, United States
  • Top Medical Research
    Cutler Bay, Florida 33189, United States
  • Palmetto Research, LLC
    Hialeah, Florida 33016, United States
  • Vida Clinical Trials
    Homestead, Florida 33030, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Panax Clinical Research, LLC.
    Miami Lakes, Florida 33014, United States
  • Savin Medical Group LLC
    Miami Lakes, Florida 33014, United States
  • APF Research LLC
    Miami, Florida 33134, United States
  • AMPM Research Clinic
    Miami, Florida 33169, United States
  • Advanced Medical Research Institute
    Miami, Florida 33174, United States
  • Florida Research Center, Inc.
    Miami, Florida 33174, United States
  • American Research Institute, Inc
    Miami, Florida 33175, United States
  • Synexus
    Pinellas Park, Florida 33781, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • River Birch Research Alliance, LLC
    Blue Ridge, Georgia 30513, United States
  • Gwinnett Research Institute, LLC
    Buford, Georgia 30519, United States
  • Summit Clinical Research, LLC.
    Carnesville, Georgia 30521, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Infinite Clinical Trials
    Riverdale, Georgia 30274, United States
  • Clinical Research Consultants of Atlanta
    Suwanee, Georgia 30024, United States
  • Rocky Mountain Diabetes and Osteoporosis Center, PA
    Idaho Falls, Idaho 83404-7596, United States
  • Southwest Gastroenterology
    Oak Lawn, Illinois 60453, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • American Research, LLC
    Jeffersonville, Indiana 47130, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Health Science Research Center
    Pratt, Kansas 67124, United States
  • WestGlen Gastrointestinal Consultants
    Shawnee Mission, Kansas 67214, United States
  • Cotton-O'Neil Clinical Research Center - Digestive Health
    Topeka, Kansas 66606, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66606, United States
  • Professional Research Network of Kansas, LLC
    Wichita, Kansas 67205, United States
  • Via Christi Clinic, PA
    Wichita, Kansas 67208, United States
  • Tri-State Gastroenterology
    Crestview Hills, Kentucky 41017, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Delta Research Partners
    Bastrop, Louisiana 71220, United States
  • WK Physicians Network
    Bossier City, Louisiana 71111, United States
  • Avant Research Associates LLC
    Crowley, Louisiana 70526, United States
  • Cronola LLC
    Houma, Louisiana 70360, United States
  • Clinical Trials of SWLA, LLC
    Lake Charles, Louisiana 70601, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • New Orleans Research Institute - Metropolitan Gastroenterology Associates
    Metairie, Louisiana 70006, United States
  • Clinical Trials of America, Inc.
    West Monroe, Louisiana 71291, United States
  • Trialspark - Silverman
    Bowie, Maryland 20716, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Frederick Gastroenterology Associates, PA an Elligo Health Research Site
    Frederick, Maryland 21701, United States
  • Woodholme Gastroenterology Associates, P.A.
    Glen Burnie, Maryland 21061, United States
  • Meridian Clinical Research, LLC
    Rockville, Maryland 20854, United States
  • Commonwealth Clinical Studies, PLLC.
    Brockton, Massachusetts 02302, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • Vida Clinical Studies
    Dearborn, Michigan 48124, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • National Clinical, LLC
    Hamtramck, Michigan 48212, United States
  • Gastroenterology Associates of Western Michigan
    Wyoming, Michigan 49519, United States
  • Minnesota Gastroenterology, P.A.
    Coon Rapids, Minnesota 55446, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • Methodist Physicians Clinic Diabetes and Endocrine Specialists
    Omaha, Nebraska 68114, United States
  • Heartland Clinical Research, Inc
    Omaha, Nebraska 68134, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Advanced Biomedical Research of America
    Las Vegas, Nevada 89123, United States
  • Digestive Disease Specialists
    Las Vegas, Nevada 89128, United States
  • Palm Research Center
    Las Vegas, Nevada 89148, United States
  • Garden State Endocrinology
    Brick, New Jersey 08723, United States
  • AGA Clinical Research Associates LLC
    Egg Harbor Township, New Jersey 08234, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87108, United States
  • Long Island Gastrointestinal Research Group LLP
    Great Neck, New York 11023, United States
  • Synexus Clinical Research US, Inc.
    Jamaica, New York 11432, United States

Showing the first 100 of 337 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Oct 2020, 33 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Feb 5, 2018
StartActual
Jan 24, 2018
Primary completionActual
Oct 30, 2020
CompletionActual
Oct 30, 2020
Results first posted
Dec 22, 2021
Last update
Dec 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03420781
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Jan 24, 2018
Primary completion
Oct 30, 2020
Completion
Oct 30, 2020
Results posted
Dec 22, 2021
Last update
Dec 22, 2021

Study contacts

Wieslaw Bochenek
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relamorelin

Start the discussion